世界の細胞性ヒト組織工学皮膚代替物市場予測 2022年-2028年

【英語タイトル】Global Cellular Human Tissue-engineered Skin Substitute Market Growth 2022-2028

LP Informationが出版した調査資料(LPI22SM18925)・商品コード:LPI22SM18925
・発行会社(調査会社):LP Information
・発行日:2022年9月
・ページ数:117
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥541,680見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥812,520見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,083,360見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

世界経済が回復するにつれて、2021年の細胞性ヒト組織工学皮膚代替物の成長は前年から大幅に変化します。LPインフォメーション社の最新の調査によると、世界の細胞性ヒト組織工学皮膚代替物市場規模は、2021年のxxxドルから2022年にはxxxドルに達し、2021年~2022年間にxxx%の変化が予想されます。2028年には世界の細胞性ヒト組織工学皮膚代替物市場規模がxxxドルまで成長し、分析期間中にxxx%のCAGRを記録すると予想されます。
アメリカの細胞性ヒト組織工学皮膚代替物市場は2021年にxxxドルの市場規模が見込まれ、分析期間中は約xxx%のCAGRで成長すると予測されます。中国は世界の細胞性ヒト組織工学皮膚代替物市場のxxx%のシェアを占め、2028年までにxxxドルに達すると展望されます。ヨーロッパの細胞性ヒト組織工学皮膚代替物の状況については、ドイツが2028年までにxxxドルに達し、分析期間にわたってCAGRがxxx%になると予測されます。アジア太平洋地域では、日本と韓国の成長率が、今後5年間でそれぞれxxx%とxxx%になると展望されます。

世界の主要な細胞性ヒト組織工学皮膚代替物プレーヤーとして、Allergan (AbbVie)、 AlloSource、 Organogenesis、 BD、 Smith & Nephew、 Integra LifeSciences、 Synthes (Johnson & Johnson)、 Axogen、 Vericel Corporation、 LifeNet Health、 MTF Biologics、 Arthrex、 Wright Medical Group NV (Stryker)、 Cook Biotech Incorporated、 Aroa Biosurgery、 Surgalign Holdingsなどをカバーしています。売上の面では、世界最大の2社が2021年に約xxx%市場シェアを占めています。

当レポートでは、製品タイプ、アプリケーション(用途)、主要メーカー、主要地域および国ごとの細胞性ヒト組織工学皮膚代替物市場の包括的な概要、市場シェア、および成長機会を掲載します。

タイプ別のセグメンテーション:2017年~2022年までの内訳データと2028年まで予測データ
同種細胞、自家細胞、その他

アプリケーション(用途)別のセグメンテーション:2017年~2022年までの内訳データと2028年まで予測データ
病院、専門クリニック、創傷治療センター

当レポートは次の地域と国の市場規模データを掲載します。
南北アメリカ(アメリカ、カナダ、メキシコ、ブラジル)
アジア太平洋(中国、日本、韓国、東南アジア、インド、オーストラリア)
ヨーロッパ(ドイツ、フランス、イギリス、イタリア、ロシア)
中東/アフリカ(エジプト、南アフリカ、イスラエル、トルコ、GCC諸国)

また、当レポートは市場の競争状況と主要メーカーの詳細な分析を掲載します。
Allergan (AbbVie)、 AlloSource、 Organogenesis、 BD、 Smith & Nephew、 Integra LifeSciences、 Synthes (Johnson & Johnson)、 Axogen、 Vericel Corporation、 LifeNet Health、 MTF Biologics、 Arthrex、 Wright Medical Group NV (Stryker)、 Cook Biotech Incorporated、 Aroa Biosurgery、 Surgalign Holdings

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要:細胞性ヒト組織工学皮膚代替物の年間販売量2017-2028、地域別現状・将来分析
・細胞性ヒト組織工学皮膚代替物のタイプ別セグメント:同種細胞、自家細胞、その他
・細胞性ヒト組織工学皮膚代替物のタイプ別販売量:2017-2022年の販売量、売上、市場シェア、販売価格
・細胞性ヒト組織工学皮膚代替物の用途別セグメント:病院、専門クリニック、創傷治療センター
・細胞性ヒト組織工学皮膚代替物の用途別販売量:2017-2022年の販売量、売上、市場シェア、販売価格

企業別世界の細胞性ヒト組織工学皮膚代替物市場
・企業別のグローバル細胞性ヒト組織工学皮膚代替物市場データ:2020-2022年の年間販売量、市場シェア
・企業別の細胞性ヒト組織工学皮膚代替物の年間売上:2020-2022年の売上、市場シェア
・企業別の細胞性ヒト組織工学皮膚代替物販売価格
・主要企業の細胞性ヒト組織工学皮膚代替物生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

細胞性ヒト組織工学皮膚代替物の地域別レビュー
・地域別の細胞性ヒト組織工学皮膚代替物市場規模2017-2022:年間販売量、売上
・主要国別の細胞性ヒト組織工学皮膚代替物市場規模2017-2022:年間販売量、売上
・南北アメリカの細胞性ヒト組織工学皮膚代替物販売の成長
・アジア太平洋の細胞性ヒト組織工学皮膚代替物販売の成長
・ヨーロッパの細胞性ヒト組織工学皮膚代替物販売の成長
・中東・アフリカの細胞性ヒト組織工学皮膚代替物販売の成長

南北アメリカ市場
・南北アメリカの国別の細胞性ヒト組織工学皮膚代替物販売量、売上(2017-2022)
・南北アメリカの細胞性ヒト組織工学皮膚代替物の種類別販売量
・南北アメリカの細胞性ヒト組織工学皮膚代替物の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の細胞性ヒト組織工学皮膚代替物販売量、売上(2017-2022)
・アジア太平洋の細胞性ヒト組織工学皮膚代替物の種類別販売量
・アジア太平洋の細胞性ヒト組織工学皮膚代替物の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の細胞性ヒト組織工学皮膚代替物販売量、売上(2017-2022)
・ヨーロッパの細胞性ヒト組織工学皮膚代替物の種類別販売量
・ヨーロッパの細胞性ヒト組織工学皮膚代替物の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の細胞性ヒト組織工学皮膚代替物販売量、売上(2017-2022)
・中東・アフリカの細胞性ヒト組織工学皮膚代替物の種類別販売量
・中東・アフリカの細胞性ヒト組織工学皮膚代替物の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・細胞性ヒト組織工学皮膚代替物の製造コスト構造分析
・細胞性ヒト組織工学皮膚代替物の製造プロセス分析
・細胞性ヒト組織工学皮膚代替物の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル:直接販売チャンネル、間接販売チャンネル
・細胞性ヒト組織工学皮膚代替物の主要なグローバル販売業者
・細胞性ヒト組織工学皮膚代替物の主要なグローバル顧客

地域別の細胞性ヒト組織工学皮膚代替物市場予測レビュー
・地域別の細胞性ヒト組織工学皮膚代替物市場規模予測(2023-2028)
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・細胞性ヒト組織工学皮膚代替物のタイプ別市場規模予測
・細胞性ヒト組織工学皮膚代替物の用途別市場規模予測

主要企業分析
Allergan (AbbVie)、 AlloSource、 Organogenesis、 BD、 Smith & Nephew、 Integra LifeSciences、 Synthes (Johnson & Johnson)、 Axogen、 Vericel Corporation、 LifeNet Health、 MTF Biologics、 Arthrex、 Wright Medical Group NV (Stryker)、 Cook Biotech Incorporated、 Aroa Biosurgery、 Surgalign Holdings
・企業情報
・細胞性ヒト組織工学皮膚代替物製品
・細胞性ヒト組織工学皮膚代替物販売量、売上、価格、粗利益(2020-2022)
・主要ビジネス概要
・最新動向

調査結果および結論

As the global economy mends, the 2021 growth of Cellular Human Tissue-engineered Skin Substitute will have significant change from previous year. According to our (LP Information) latest study, the global Cellular Human Tissue-engineered Skin Substitute market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Cellular Human Tissue-engineered Skin Substitute market size will reach USD million in 2028, growing at a CAGR of % over the analysis period 2022-2028.
The United States Cellular Human Tissue-engineered Skin Substitute market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Cellular Human Tissue-engineered Skin Substitute market, reaching US$ million by the year 2028. As for the Europe Cellular Human Tissue-engineered Skin Substitute landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main Cellular Human Tissue-engineered Skin Substitute players cover Allergan (AbbVie), AlloSource, Organogenesis, and BD, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Cellular Human Tissue-engineered Skin Substitute market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Cellular Allogeneic
Cellular Autologous
Others
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Hospitals
Specialty Clinics
Wound Care Centers
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Allergan (AbbVie)
AlloSource
Organogenesis
BD
Smith & Nephew
Integra LifeSciences
Synthes (Johnson & Johnson)
Axogen
Vericel Corporation
LifeNet Health
MTF Biologics
Arthrex
Wright Medical Group NV (Stryker)
Cook Biotech Incorporated
Aroa Biosurgery
Surgalign Holdings

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cellular Human Tissue-engineered Skin Substitute Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Cellular Human Tissue-engineered Skin Substitute by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Cellular Human Tissue-engineered Skin Substitute by Country/Region, 2017, 2022 & 2028
2.2 Cellular Human Tissue-engineered Skin Substitute Segment by Type
2.2.1 Cellular Allogeneic
2.2.2 Cellular Autologous
2.2.3 Others
2.3 Cellular Human Tissue-engineered Skin Substitute Sales by Type
2.3.1 Global Cellular Human Tissue-engineered Skin Substitute Sales Market Share by Type (2017-2022)
2.3.2 Global Cellular Human Tissue-engineered Skin Substitute Revenue and Market Share by Type (2017-2022)
2.3.3 Global Cellular Human Tissue-engineered Skin Substitute Sale Price by Type (2017-2022)
2.4 Cellular Human Tissue-engineered Skin Substitute Segment by Application
2.4.1 Hospitals
2.4.2 Specialty Clinics
2.4.3 Wound Care Centers
2.5 Cellular Human Tissue-engineered Skin Substitute Sales by Application
2.5.1 Global Cellular Human Tissue-engineered Skin Substitute Sale Market Share by Application (2017-2022)
2.5.2 Global Cellular Human Tissue-engineered Skin Substitute Revenue and Market Share by Application (2017-2022)
2.5.3 Global Cellular Human Tissue-engineered Skin Substitute Sale Price by Application (2017-2022)
3 Global Cellular Human Tissue-engineered Skin Substitute by Company
3.1 Global Cellular Human Tissue-engineered Skin Substitute Breakdown Data by Company
3.1.1 Global Cellular Human Tissue-engineered Skin Substitute Annual Sales by Company (2020-2022)
3.1.2 Global Cellular Human Tissue-engineered Skin Substitute Sales Market Share by Company (2020-2022)
3.2 Global Cellular Human Tissue-engineered Skin Substitute Annual Revenue by Company (2020-2022)
3.2.1 Global Cellular Human Tissue-engineered Skin Substitute Revenue by Company (2020-2022)
3.2.2 Global Cellular Human Tissue-engineered Skin Substitute Revenue Market Share by Company (2020-2022)
3.3 Global Cellular Human Tissue-engineered Skin Substitute Sale Price by Company
3.4 Key Manufacturers Cellular Human Tissue-engineered Skin Substitute Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cellular Human Tissue-engineered Skin Substitute Product Location Distribution
3.4.2 Players Cellular Human Tissue-engineered Skin Substitute Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Cellular Human Tissue-engineered Skin Substitute by Geographic Region
4.1 World Historic Cellular Human Tissue-engineered Skin Substitute Market Size by Geographic Region (2017-2022)
4.1.1 Global Cellular Human Tissue-engineered Skin Substitute Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Cellular Human Tissue-engineered Skin Substitute Annual Revenue by Geographic Region
4.2 World Historic Cellular Human Tissue-engineered Skin Substitute Market Size by Country/Region (2017-2022)
4.2.1 Global Cellular Human Tissue-engineered Skin Substitute Annual Sales by Country/Region (2017-2022)
4.2.2 Global Cellular Human Tissue-engineered Skin Substitute Annual Revenue by Country/Region
4.3 Americas Cellular Human Tissue-engineered Skin Substitute Sales Growth
4.4 APAC Cellular Human Tissue-engineered Skin Substitute Sales Growth
4.5 Europe Cellular Human Tissue-engineered Skin Substitute Sales Growth
4.6 Middle East & Africa Cellular Human Tissue-engineered Skin Substitute Sales Growth
5 Americas
5.1 Americas Cellular Human Tissue-engineered Skin Substitute Sales by Country
5.1.1 Americas Cellular Human Tissue-engineered Skin Substitute Sales by Country (2017-2022)
5.1.2 Americas Cellular Human Tissue-engineered Skin Substitute Revenue by Country (2017-2022)
5.2 Americas Cellular Human Tissue-engineered Skin Substitute Sales by Type
5.3 Americas Cellular Human Tissue-engineered Skin Substitute Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cellular Human Tissue-engineered Skin Substitute Sales by Region
6.1.1 APAC Cellular Human Tissue-engineered Skin Substitute Sales by Region (2017-2022)
6.1.2 APAC Cellular Human Tissue-engineered Skin Substitute Revenue by Region (2017-2022)
6.2 APAC Cellular Human Tissue-engineered Skin Substitute Sales by Type
6.3 APAC Cellular Human Tissue-engineered Skin Substitute Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Cellular Human Tissue-engineered Skin Substitute by Country
7.1.1 Europe Cellular Human Tissue-engineered Skin Substitute Sales by Country (2017-2022)
7.1.2 Europe Cellular Human Tissue-engineered Skin Substitute Revenue by Country (2017-2022)
7.2 Europe Cellular Human Tissue-engineered Skin Substitute Sales by Type
7.3 Europe Cellular Human Tissue-engineered Skin Substitute Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cellular Human Tissue-engineered Skin Substitute by Country
8.1.1 Middle East & Africa Cellular Human Tissue-engineered Skin Substitute Sales by Country (2017-2022)
8.1.2 Middle East & Africa Cellular Human Tissue-engineered Skin Substitute Revenue by Country (2017-2022)
8.2 Middle East & Africa Cellular Human Tissue-engineered Skin Substitute Sales by Type
8.3 Middle East & Africa Cellular Human Tissue-engineered Skin Substitute Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cellular Human Tissue-engineered Skin Substitute
10.3 Manufacturing Process Analysis of Cellular Human Tissue-engineered Skin Substitute
10.4 Industry Chain Structure of Cellular Human Tissue-engineered Skin Substitute
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cellular Human Tissue-engineered Skin Substitute Distributors
11.3 Cellular Human Tissue-engineered Skin Substitute Customer
12 World Forecast Review for Cellular Human Tissue-engineered Skin Substitute by Geographic Region
12.1 Global Cellular Human Tissue-engineered Skin Substitute Market Size Forecast by Region
12.1.1 Global Cellular Human Tissue-engineered Skin Substitute Forecast by Region (2023-2028)
12.1.2 Global Cellular Human Tissue-engineered Skin Substitute Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Cellular Human Tissue-engineered Skin Substitute Forecast by Type
12.7 Global Cellular Human Tissue-engineered Skin Substitute Forecast by Application
13 Key Players Analysis
13.1 Allergan (AbbVie)
13.1.1 Allergan (AbbVie) Company Information
13.1.2 Allergan (AbbVie) Cellular Human Tissue-engineered Skin Substitute Product Offered
13.1.3 Allergan (AbbVie) Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Allergan (AbbVie) Main Business Overview
13.1.5 Allergan (AbbVie) Latest Developments
13.2 AlloSource
13.2.1 AlloSource Company Information
13.2.2 AlloSource Cellular Human Tissue-engineered Skin Substitute Product Offered
13.2.3 AlloSource Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 AlloSource Main Business Overview
13.2.5 AlloSource Latest Developments
13.3 Organogenesis
13.3.1 Organogenesis Company Information
13.3.2 Organogenesis Cellular Human Tissue-engineered Skin Substitute Product Offered
13.3.3 Organogenesis Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Organogenesis Main Business Overview
13.3.5 Organogenesis Latest Developments
13.4 BD
13.4.1 BD Company Information
13.4.2 BD Cellular Human Tissue-engineered Skin Substitute Product Offered
13.4.3 BD Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 BD Main Business Overview
13.4.5 BD Latest Developments
13.5 Smith & Nephew
13.5.1 Smith & Nephew Company Information
13.5.2 Smith & Nephew Cellular Human Tissue-engineered Skin Substitute Product Offered
13.5.3 Smith & Nephew Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Smith & Nephew Main Business Overview
13.5.5 Smith & Nephew Latest Developments
13.6 Integra LifeSciences
13.6.1 Integra LifeSciences Company Information
13.6.2 Integra LifeSciences Cellular Human Tissue-engineered Skin Substitute Product Offered
13.6.3 Integra LifeSciences Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Integra LifeSciences Main Business Overview
13.6.5 Integra LifeSciences Latest Developments
13.7 Synthes (Johnson & Johnson)
13.7.1 Synthes (Johnson & Johnson) Company Information
13.7.2 Synthes (Johnson & Johnson) Cellular Human Tissue-engineered Skin Substitute Product Offered
13.7.3 Synthes (Johnson & Johnson) Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Synthes (Johnson & Johnson) Main Business Overview
13.7.5 Synthes (Johnson & Johnson) Latest Developments
13.8 Axogen
13.8.1 Axogen Company Information
13.8.2 Axogen Cellular Human Tissue-engineered Skin Substitute Product Offered
13.8.3 Axogen Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Axogen Main Business Overview
13.8.5 Axogen Latest Developments
13.9 Vericel Corporation
13.9.1 Vericel Corporation Company Information
13.9.2 Vericel Corporation Cellular Human Tissue-engineered Skin Substitute Product Offered
13.9.3 Vericel Corporation Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Vericel Corporation Main Business Overview
13.9.5 Vericel Corporation Latest Developments
13.10 LifeNet Health
13.10.1 LifeNet Health Company Information
13.10.2 LifeNet Health Cellular Human Tissue-engineered Skin Substitute Product Offered
13.10.3 LifeNet Health Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 LifeNet Health Main Business Overview
13.10.5 LifeNet Health Latest Developments
13.11 MTF Biologics
13.11.1 MTF Biologics Company Information
13.11.2 MTF Biologics Cellular Human Tissue-engineered Skin Substitute Product Offered
13.11.3 MTF Biologics Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 MTF Biologics Main Business Overview
13.11.5 MTF Biologics Latest Developments
13.12 Arthrex
13.12.1 Arthrex Company Information
13.12.2 Arthrex Cellular Human Tissue-engineered Skin Substitute Product Offered
13.12.3 Arthrex Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Arthrex Main Business Overview
13.12.5 Arthrex Latest Developments
13.13 Wright Medical Group NV (Stryker)
13.13.1 Wright Medical Group NV (Stryker) Company Information
13.13.2 Wright Medical Group NV (Stryker) Cellular Human Tissue-engineered Skin Substitute Product Offered
13.13.3 Wright Medical Group NV (Stryker) Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Wright Medical Group NV (Stryker) Main Business Overview
13.13.5 Wright Medical Group NV (Stryker) Latest Developments
13.14 Cook Biotech Incorporated
13.14.1 Cook Biotech Incorporated Company Information
13.14.2 Cook Biotech Incorporated Cellular Human Tissue-engineered Skin Substitute Product Offered
13.14.3 Cook Biotech Incorporated Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Cook Biotech Incorporated Main Business Overview
13.14.5 Cook Biotech Incorporated Latest Developments
13.15 Aroa Biosurgery
13.15.1 Aroa Biosurgery Company Information
13.15.2 Aroa Biosurgery Cellular Human Tissue-engineered Skin Substitute Product Offered
13.15.3 Aroa Biosurgery Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Aroa Biosurgery Main Business Overview
13.15.5 Aroa Biosurgery Latest Developments
13.16 Surgalign Holdings
13.16.1 Surgalign Holdings Company Information
13.16.2 Surgalign Holdings Cellular Human Tissue-engineered Skin Substitute Product Offered
13.16.3 Surgalign Holdings Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 Surgalign Holdings Main Business Overview
13.16.5 Surgalign Holdings Latest Developments
14 Research Findings and Conclusion



★調査レポート[世界の細胞性ヒト組織工学皮膚代替物市場予測 2022年-2028年] (コード:LPI22SM18925)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の細胞性ヒト組織工学皮膚代替物市場予測 2022年-2028年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆